Righton Gene announced on April 9 that in 2022, the company achieved operating revenue of CNY 424 million, up 45.83% year-on-year; attributable net profit of CNY 40,473,600, down 14.49% year-on-year; basic earnings per share of CNY 0.73.

In 2022, the company achieved operating revenue of CNY 220,770,800,000 for the conventional clinical laboratory self-build project, up 581.10% from the previous year. The growth mainly came from the COVID testing business in some regions in Shanghai. In 2022, blood disease molecular diagnostic kits products achieved revenue of CNY 147,137,600, down 15.68% from the previous year, of which, leukemia molecular test kits revenue of CNY 127,597,500, down 17.72%; lymphoma rearrangement test kits achieved product and service revenue of CNY19,540,100.

Company Main Business Information

Righton Gene is a life science company focusing on the field of oncology, with its own brand of testing instruments, testing reagents and third-party laboratories. Since its establishment, the company has been actively committed to the national strategy of "precision medicine", with the mission of "saving more people from tumors" and the vision of "becoming the most trusted genetic company". Our vision is to be the most trusted genetic company. The company will continue to uphold the core values of "real people, real heart, real ability" and the business philosophy of "knowledge is more than facts, leadership comes from innovation", and is determined to become the best in vitro diagnostic company in the field of cancer precision testing.

The company's main business is the research and development, production, sales, scientific research and testing services of in vitro diagnostic products (including testing instruments and testing reagents), mainly providing genetic and antigenic precision testing for patients with hematological diseases (leukemia, lymphoma), solid tumors (lung cancer, colorectal cancer, melanoma, etc.) and infectious diseases (hepatitis B, rubella, herpes simplex, etc.), providing individual diagnosis, risk assessment, disease typing, targeting, drug selection and efficacy monitoring. It provides the basis for the development of individualized treatment plans such as disease diagnosis, risk assessment, disease typing, targeted drug selection and efficacy monitoring. At the same time, the company is also vigorously expanding its immunodiagnostic antigen detection reagents, which are mainly used for initial screening, follow-up and review of leukemia patients, becoming a strong complement to the company's leukemia products.